Kevin McAllister, PhD, MBA

Dr. Kevin McAllister is Head of Research & Development at Ultimate Medicine, guiding the company’s scientific direction and early-stage development of therapeutics targeting gut-brain metabolites involved in cognitive decline. A neuroscience drug-development leader and serial biotech entrepreneur, he brings more than 25 years of experience advancing CNS programs from discovery through Phase 2.

Before joining Ultimate Medicine, Dr. McAllister founded and led multiple biotechnology ventures, including Amphilix AG and SOM Innovation Biotech SA, and previously served as Head of Neurology & Neuropsychiatry at Novartis, where his teams discovered six new chemical entities and achieved five positive proof-of-concept studies. His expertise spans translational medicine, radioligand therapeutics, and neurodegenerative disorders such as Huntington’s disease and Fragile X syndrome.

Dr. McAllister earned his PhD in Pharmacology from the University of Wales, completed postdoctoral research at Louisiana State University, and received an MBA from IMD Business School in Switzerland.

At Ultimate Medicine, he drives the translation of breakthrough gut-brain science into clinically actionable therapies for cognitive disorders.